Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.

@article{Drake2013ChronicCT,
  title={Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.},
  author={Jennifer I. Drake and Jose G. Gomez-Arroyo and Catherine I. Dumur and Donatas Kraskauskas and Ramesh Natarajan and Harm Jan Bogaard and P. A. Fawcett and Norbert Felix Voelkel},
  journal={Physiological genomics},
  year={2013},
  volume={45 12},
  pages={449-61}
}
Right ventricular failure (RVF) is the most frequent cause of death in patients with pulmonary arterial hypertension (PAH); however, specific therapies targeted to treat RVF have not been developed. Chronic treatment with carvedilol has been shown to reduce established maladaptive right ventricle (RV) hypertrophy and to improve RV function in experimental PAH. However, the mechanisms by which carvedilol improves RVF are unknown. We have previously demonstrated by microarray analysis that RVF is… CONTINUE READING